Akt/SKG Substrate PeptideAkt/PKB substrate (synthetic) CAS# 276680-69-4 |
- MK-2206 dihydrochloride
Catalog No.:BCC1274
CAS No.:1032350-13-2
- Perifosine
Catalog No.:BCC3673
CAS No.:157716-52-4
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- Temsirolimus
Catalog No.:BCC3678
CAS No.:162635-04-3
- Rapamycin (Sirolimus)
Catalog No.:BCC3592
CAS No.:53123-88-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 276680-69-4 | SDF | Download SDF |
| PubChem ID | 10440446 | Appearance | Powder |
| Formula | C36H59N13O9 | M.Wt | 817.95 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 1 mg/ml in water | ||
| Sequence | RPRAATF | ||
| Chemical Name | (2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]propanoyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoic acid | ||
| SMILES | CC(C(C(=O)NC(CC1=CC=CC=C1)C(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C2CCCN2C(=O)C(CCCN=C(N)N)N)O | ||
| Standard InChIKey | XXOREQHVEARXEP-WDKSWFFASA-N | ||
| Standard InChI | InChI=1S/C36H59N13O9/c1-19(28(51)44-20(2)29(52)48-27(21(3)50)32(55)47-25(34(57)58)18-22-10-5-4-6-11-22)45-30(53)24(13-8-16-43-36(40)41)46-31(54)26-14-9-17-49(26)33(56)23(37)12-7-15-42-35(38)39/h4-6,10-11,19-21,23-27,50H,7-9,12-18,37H2,1-3H3,(H,44,51)(H,45,53)(H,46,54)(H,47,55)(H,48,52)(H,57,58)(H4,38,39,42)(H4,40,41,43)/t19-,20-,21+,23-,24-,25-,26-,27-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Synthetic peptide suitable as a substrate for Akt/PKB. Unlike other substrates, it is not phosphorylated by p70 S6 kinase or MAP kinase activated protein kinase-1. |
Akt/SKG Substrate Peptide Dilution Calculator
Akt/SKG Substrate Peptide Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Leucoside
Catalog No.:BCN5167
CAS No.:27661-51-4
- Cyanidin-3-O-galactoside chloride
Catalog No.:BCN3022
CAS No.:27661-36-5
- Boc-Ser-OMe
Catalog No.:BCC3441
CAS No.:2766-43-0
- 5-Isoquinolinesulfonic acid
Catalog No.:BCC8749
CAS No.:27655-40-9
- 15-Nonacosanol
Catalog No.:BCC8439
CAS No.:2764-81-0
- Muscimol
Catalog No.:BCC6593
CAS No.:2763-96-4
- Rhodexin B
Catalog No.:BCC8246
CAS No.:2763-20-4
- Danaidal
Catalog No.:BCN1965
CAS No.:27628-46-2
- Communic acid
Catalog No.:BCN5166
CAS No.:2761-77-5
- MMF
Catalog No.:BCC7941
CAS No.:2756-87-8
- Baccatin III
Catalog No.:BCN5165
CAS No.:27548-93-2
- MS 245 oxalate
Catalog No.:BCC6127
CAS No.:275363-58-1
- WAY 161503 hydrochloride
Catalog No.:BCC7179
CAS No.:276695-22-8
- Cryptomoscatone D2
Catalog No.:BCN7203
CAS No.:276856-55-4
- 7-Megastigmene-3,5,6,9-tetraol
Catalog No.:BCN5168
CAS No.:276870-26-9
- 2,4-Bis(α,α-dimethylbenzyl)phenol
Catalog No.:BCC8498
CAS No.:2772-45-4
- Scutellarin
Catalog No.:BCN5902
CAS No.:27740-01-8
- Erysotrine
Catalog No.:BCN5170
CAS No.:27740-43-8
- Geniposidic acid
Catalog No.:BCN5171
CAS No.:27741-01-1
- Pahutoxin
Catalog No.:BCN1811
CAS No.:27742-14-9
- 5-Hydroxy-1-methoxyxanthone
Catalog No.:BCN6575
CAS No.:27770-13-4
- Ervamycine
Catalog No.:BCN5172
CAS No.:27773-39-3
- 9-Angeloylretronecine N-oxide
Catalog No.:BCN2037
CAS No.:27773-86-0
- Uncarinic acid E
Catalog No.:BCN6774
CAS No.:277751-61-8
Ultrasensitive and absolute quantification of the phosphoinositide 3-kinase/Akt signal transduction pathway by mass spectrometry.[Pubmed:16751276]
Proc Natl Acad Sci U S A. 2006 Jun 13;103(24):8959-64.
The phosphoinositide 3-kinase (PI3K)/Akt pathway controls a vast array of normal physiological processes and is frequently aberrantly activated in cancer, thus identifying PI3K/Akt-signaling components as promising drug targets in oncology. However, implementation of rational cancer therapies for this pathway needs robust and simple tools to stratify patients according to PI3K pathway activation and to validate and measure the impact of targeted inhibition on primary cancer tissues. Herein we present a technique for the quantification of the PI3K/Akt-signaling pathway based on the mass spectrometric measurement of PI3K-dependent protein kinase activity in cell lysates. The concept of this application of MS is to exploit enzymatic activity to amplify the signal of the enzyme under study analogous to the PCR used to amplify nucleic acid sequences. We show that this approach allows quantitative analysis of a cell-signaling pathway with high sensitivity, precision of quantification, and specificity. Due to its special analytical capabilities and potential for multiplexing, this approach could contribute significantly to cell-signaling studies and to the development and implementation of personalized cancer therapies.
Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase.[Pubmed:8985174]
FEBS Lett. 1996 Dec 16;399(3):333-8.
The substrate specificity of protein kinase-B alpha (PKBalpha, also known as RAC kinase or Akt) was investigated using synthetic peptide substrates related to the sequence surrounding the phosphorylation site on glycogen synthase kinase-3 (GSK3). The minimum sequence motif required for efficient phosphorylation was Arg-Xaa-Arg-Yaa-Zaa-Ser/Thr-Hyd, where Xaa is any amino acid, Yaa and Zaa are small residues other than glycine and Hyd is a bulky hydrophobic residue (Phe, Leu). The most effective substrate, Arg-Pro-Arg-Thr-Ser-Ser-Phe, was phosphorylated with a Km of 5 microM and Vmax of 260 U/mg. PKBalpha phosphorylated histone H2B (Km 5 microM, Vmax 68 U/mg) specifically at Ser-36 which also lies in an Arg-Xaa-Arg-Xaa-Xaa-Ser-Hyd motif. The peptide Arg-Pro-Arg-Ala-Ala-Thr-Phe may be a relatively specific substrate for PKBalpha because, unlike other substrates, it is not phosphorylated by p70 S6 kinase or MAP kinase activated protein (MAPKAP) kinase-1.
